

Cyclophosphamide versus ifosfamide: Final report of a r soft tissue sarcomas

European Journal of Cancer & Clinical Oncology

23, 311-321

DOI: 10.1016/0277-5379(87)90075-7

Citation Report

#	ARTICLE	IF	CITATIONS
1	A phase II study of ifosfamide/mesna with doxorubicin for adult soft tissue sarcoma. <i>Cancer Chemotherapy and Pharmacology</i> , 1988, 21, 49-52.	1.1	21
2	Review of the clinical trials activity of the soft tissue and bone sarcoma group of the european organization for research and treatment of cancer. <i>Journal of Surgical Oncology</i> , 1988, 4, 45-52.	1.4	3
3	A phase II study of ifosfamide in combination with adriamycin in the treatment of adult soft tissue sarcoma. <i>European Journal of Cancer & Clinical Oncology</i> , 1988, 24, 1439-1443.	0.9	36
4	FATAL HYPOKALAEMIA ASSOCIATED WITH IFOSFAMIDE/MESNA CHEMOTHERAPY. <i>Lancet, The</i> , 1988, 331, 1116.	6.3	17
5	Ifosfamide: An old drug recently rediscovered. <i>European Journal of Cancer & Clinical Oncology</i> , 1988, 24, 959-961.	0.9	2
6	Salvage Therapy in Recurrent Germ Cell Cancer: Ifosfamide and Cisplatin plus Either Vinblastine or Etoposide. <i>Annals of Internal Medicine</i> , 1988, 109, 540.	2.0	249
7	Ifosfamide and mesna: marginally active in patients with advanced carcinoma of the pancreas.. <i>Journal of Clinical Oncology</i> , 1988, 6, 1703-1707.	0.8	50
8	Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy.. <i>Journal of Clinical Oncology</i> , 1989, 7, 1208-1216.	0.8	263
9	Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group Study.. <i>Journal of Clinical Oncology</i> , 1989, 7, 1672-1676.	0.8	118
10	Ifosfamide plus doxorubicin in metastatic adult sarcomas: a multi-institutional phase II trial.. <i>Journal of Clinical Oncology</i> , 1989, 7, 1655-1659.	0.8	65
11	Soft tissue sarcomas: Current trends in diagnosis and management. <i>Current Problems in Cancer</i> , 1989, 13, 340-369.	1.0	52
12	The place of chemotherapy in the management of soft tissue sarcoma: Experiences of the EORTC soft tissue and bone sarcoma group. <i>Clinical Oncology</i> , 1989, 1, 106-109.	0.6	6
13	Ifosfamide in pediatric malignant solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 1989, 24, S24-7.	1.1	32
14	The efficacy and safety of GR38032F in the prophylaxis of ifosfamide-induced nausea and vomiting. <i>Cancer Chemotherapy and Pharmacology</i> , 1989, 24, 137-9.	1.1	9
15	Ifosfamide: A clinical review. <i>Seminars in Oncology Nursing</i> , 1989, 5, 70-77.	0.7	11
16	Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (A Gynecologic) Tj ETQq1 1 0.784314 rgBT /Overlock 140	0.7	140
17	Clinical Pharmacology of Cancer Chemotherapy in Children. <i>Pediatric Clinics of North America</i> , 1989, 36, 1199-1230.	0.9	31
18	Epidoxorubicin plus ifosfamide in advanced and/or metastatic soft-tissue sarcomas. <i>Cancer Chemotherapy and Pharmacology</i> , 1990, 26, 453-456.	1.1	10

#	ARTICLE	IF	CITATIONS
19	Dose intensity of carboplatin in combination with cyclophosphamide or ifosfamide. <i>Cancer Chemotherapy and Pharmacology</i> , 1990, 26, S22-S25.	1.1	8
20	Ifosfamide with and without Adriamycin in advanced uterine leiomyosarcoma. <i>Cancer Chemotherapy and Pharmacology</i> , 1990, 26, S26-S29.	1.1	13
21	The role of chemotherapy including ifosfamide for ovarian carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 1990, 26, S30-S32.	1.1	0
22	Early phase II Gynecologic Oncology Group experience with ifosfamide/mesna in gynecologic malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 1990, 26, S55-S58.	1.1	8
23	Experience of the Belgian Society of Medical Oncology with single-administration 5 g/m ² ifosfamide with mesna as second- or third-line therapy in advanced breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1990, 26, S63-S65.	1.1	7
24	Ifosfamide + mitoxantrone in advanced breast cancer previously treated with anthracyclines. <i>Cancer Chemotherapy and Pharmacology</i> , 1990, 26, S81-S84.	1.1	13
25	Ifosfamide/etoposide and mesna uroprotection in advanced breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1990, 26, S87-S90.	1.1	11
26	Phase II trial of 6-diazo-5-oxo-L-norleucine versus aclacinomycin-A in advanced sarcomas and mesotheliomas. <i>Investigational New Drugs</i> , 1990, 8, 113-9.	1.2	47
27	Progress in the recognition and treatment of soft tissue sarcomas. <i>Cancer</i> , 1990, 65, 660-666.	2.0	42
28	Randomized comparison of doxorubicin and vindesine to doxorubicin for patients with metastatic soft-tissue sarcomas. <i>Cancer</i> , 1990, 66, 862-867.	2.0	71
29	High-dose ifosfamide with mesna uroprotection: a phase I study.. <i>Journal of Clinical Oncology</i> , 1990, 8, 170-178.	0.8	135
30	Ifosfamide in paediatric oncology: tried but not tested?. <i>Lancet, The</i> , 1990, 335, 1022-1023.	6.3	27
31	Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. <i>European Journal of Cancer & Clinical Oncology</i> , 1990, 26, 558-561.	0.9	78
32	Doxorubicin in relapsed soft tissue sarcoma: Justification of phase II evaluation of new drugs in this disease. <i>European Journal of Cancer & Clinical Oncology</i> , 1990, 26, 139-141.	0.9	24
33	Clinical oncology: Case presentations from oncology centres 1. Ewing's sarcoma. <i>European Journal of Cancer & Clinical Oncology</i> , 1991, 27, 1525-1533.	0.9	3
34	Ifosfamide/Mesna. <i>Drugs</i> , 1991, 42, 428-467.	4.9	159
35	A phase I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support.. <i>Journal of Clinical Oncology</i> , 1991, 9, 320-327.	0.8	48
36	Ambulatory high-dose 5-day continuous-infusion ifosfamide combination chemotherapy in advanced solid tumors: a feasibility study. <i>Journal of Cancer Research and Clinical Oncology</i> , 1991, 117, S125-S128.	1.2	12

#	ARTICLE	IF	CITATIONS
37	Subcutaneous continuous infusion of ifosfamide and cyclophosphamide in ambulatory cancer patients: bioavailability and feasibility. <i>Journal of Cancer Research and Clinical Oncology</i> , 1991, 117, S129-S134.	1.2	5
38	Dosing and side-effects of ifosfamide plus mesna. <i>Journal of Cancer Research and Clinical Oncology</i> , 1991, 117, S164-S186.	1.2	31
39	Doxorubicin plus ifosfamide with rhGM-CSF in the treatment of advanced adult soft-tissue sarcomas: preliminary results of a phase II study from the EORTC Soft-Tissue and Bone Sarcoma Group. <i>Journal of Cancer Research and Clinical Oncology</i> , 1991, 117, S193-S197.	1.2	14
40	Escalating doses of carboplatin with high-dose ifosfamide using autologous bone marrow as support: a phase I study. <i>Journal of Cancer Research and Clinical Oncology</i> , 1991, 117, S208-S213.	1.2	2
41	Chemotherapy for metastatic soft tissue sarcomas – another full circle?. <i>British Journal of Cancer</i> , 1991, 64, 7-9.	2.9	19
42	Current status of etoposide in the management of small cell lung cancer. <i>Cancer</i> , 1991, 67, 231-244.	2.0	50
43	Sarcomas of soft tissue and bone. <i>Cancer</i> , 1991, 68, 463-473.	2.0	69
44	A phase II trial of PALA+dipyridamole in patients with advanced soft-tissue sarcoma. <i>Cancer Chemotherapy and Pharmacology</i> , 1991, 28, 51-54.	1.1	11
45	Chemotherapy in the multidisciplinary approach to soft tissue sarcomas. <i>Annals of Oncology</i> , 1992, 3, S75-S80.	0.6	21
46	Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: A Gynecologic Oncology Group study. <i>American Journal of Obstetrics and Gynecology</i> , 1992, 166, 556-559.	0.7	150
47	Ifosfamide, vincristine, doxorubicin and dacarbazine in adult patients with advanced soft-tissue sarcoma. <i>Cancer Chemotherapy and Pharmacology</i> , 1992, 30, 100-104.	1.1	11
48	Future directions in the management of soft tissue sarcomas. <i>Hematological Oncology</i> , 1992, 10, 53-60.	0.8	6
49	Etoposide, Ifosfamide, and Cisplatin in Extensive Small Cell Lung Cancer. <i>Cancer</i> , 1992, 69, 669-673.	2.0	33
50	A phase II trial of ifosfamide in previously untreated children and adolescents with unresectable rhabdomyosarcoma. <i>Cancer</i> , 1993, 71, 2119-2125.	2.0	42
51	Ambulatory continuous infusion ifosfamide with oral etoposide in advanced sarcomas. <i>Cancer</i> , 1993, 72, 2963-2969.	2.0	41
52	Ifosfamide/carboplatin/etoposide (ICE) regimen in small cell lung cancer. <i>Lung Cancer</i> , 1993, 9, S51-S67.	0.9	9
53	Extensive small cell lung cancer: trials of Indiana University and the Hoosier Oncology Group. <i>Lung Cancer</i> , 1993, 9, S41-S49.	0.9	2
54	Chemotherapy administration and data collection in an EORTC collaborative group – Can we trust the results?. <i>European Journal of Cancer</i> , 1993, 29, 943-947.	1.3	36

#	ARTICLE	IF	CITATIONS
55	Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.. Journal of Clinical Oncology, 1993, 11, 15-21.	0.8	150
56	An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.. Journal of Clinical Oncology, 1993, 11, 1276-1285.	0.8	438
57	Ifosfamide, mesna, and nephrotoxicity in children.. Journal of Clinical Oncology, 1993, 11, 173-190.	0.8	225
58	Systemic Adjuvant Chemotherapy for Soft Tissue Sarcomas of the Extremities. Surgical Oncology Clinics of North America, 1993, 2, 621-637.	0.6	13
59	The effect of chemotherapy on the different components of advanced carcinosarcomas (malignant) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 Cancer, 1994, 4, 52-60.	1.2	34
60	Synovial sarcoma. Uniform response of metastases to high dose ifosfamide. Cancer, 1994, 73, 2506-2511.	2.0	263
61	The use of hematological growth factors to enable dose intensification in chemotherapy for soft tissue sarcomas. Stem Cells, 1994, 12, 402-408.	1.4	2
62	Soft tissue sarcomas in adults. Ca-A Cancer Journal for Clinicians, 1994, 44, 200-210.	157.7	20
63	VP-16, ifosfamide and cisplatin (VIP) for extensive small cell lung cancer. European Journal of Cancer, 1994, 30, 299-303.	1.3	13
64	Ifosfamide Clinical Pharmacokinetics. Clinical Pharmacokinetics, 1994, 26, 439-456.	1.6	87
65	Phase II study with Docetaxel (Taxotere®) in advanced soft tissue sarcomas of the adult. Annals of Oncology, 1994, 5, 539-542.	0.6	127
66	The present state of the art in chemotherapy for soft tissue sarcomas in adults: the EORTC point of view. Critical Reviews in Oncology/Hematology, 1995, 20, 193-201.	2.0	47
67	The art of limb salvage in musculoskeletal oncology. Critical Reviews in Oncology/Hematology, 1995, 21, 77-103.	2.0	18
68	New Drugs for the Treatment of Sarcomas. Hematology/Oncology Clinics of North America, 1995, 9, 909-926.	0.9	15
69	High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas.. Journal of Clinical Oncology, 1995, 13, 1600-1608.	0.8	193
70	Phase II study of ifosfamide, carboplatin, and oral etoposide chemotherapy for extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group pilot study.. Journal of Clinical Oncology, 1995, 13, 1615-1622.	0.8	39
71	Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.. Journal of Clinical Oncology, 1995, 13, 1537-1545.	0.8	488
72	Results of Single-Agent and Combination Chemotherapy for Advanced Soft Tissue Sarcomas: Implication for Decision Making in the Clinic. Hematology/Oncology Clinics of North America, 1995, 9, 765-786.	0.9	92

#	ARTICLE	IF	CITATIONS
74	Soft tissue sarcomas. <i>Current Problems in Surgery</i> , 1996, 33, 820-872.	0.6	204
75	Phase II study of second-line treatment with high-dose cyclophosphamide in recurrent metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1996, 37, 377-381.	1.1	1
76	The history of the oxazaphosphorine cytostatics. , 1996, 78, 542-547.		37
77	Phase II Study of Ifosfamide and Etoposide Chemotherapy for Extensive-Disease Small-Cell Lung Cancer. <i>Japanese Journal of Clinical Oncology</i> , 1997, 27, 76-79.	0.6	3
78	Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas. <i>Annals of Oncology</i> , 1997, 8, 1159-1162.	0.6	55
79	Chemotherapy for soft tissue sarcomas. <i>Acta Orthopaedica</i> , 1997, 68, 133-138.	1.4	11
80	Should high-dose chemotherapy be used in the treatment of soft tissue sarcoma?. <i>European Journal of Cancer</i> , 1997, 33, 1359-1360.	1.3	0
81	Should high-dose chemotherapy be used in the treatment of soft tissue sarcoma?. <i>European Journal of Cancer</i> , 1997, 33, 1354-1359.	1.3	0
82	Should high-dose chemotherapy be used in the treatment of soft tissue sarcoma?. <i>European Journal of Cancer</i> , 1997, 33, 1351-1354.	1.3	9
83	Haemangiopericytoma of the heart: report of a case with combined modality treatment. <i>European Journal of Surgical Oncology</i> , 1997, 23, 459-461.	0.5	2
84	Synovial sarcoma: immunohistochemical expression of p-glycoprotein and glutathione s-transferase-pi and clinical drug resistance. <i>Pathology Research and Practice</i> , 1997, 193, 21-36.	1.0	9
85	High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence.. <i>Journal of Clinical Oncology</i> , 1997, 15, 2378-2384.	0.8	236
86	Phase II study of vinorelbine and ifosfamide in anthracycline resistant metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 1997, 42, 183-186.	1.1	10
87	6-day continuous infusion of high-dose ifosfamide with bone marrow growth factors in advanced refractory malignancies. <i>Journal of Cancer Research and Clinical Oncology</i> , 1997, 123, 227-231.	1.2	4
88	Modulation of P450-dependent ifosfamide pharmacokinetics: a better understanding of drug activation in vivo. <i>British Journal of Cancer</i> , 1998, 77, 1768-1776.	2.9	30
89	Characterization of human soft-tissue sarcoma xenografts for use in secondary drug screening. <i>British Journal of Cancer</i> , 1998, 78, 1586-1593.	2.9	9
90	A pilot study of vincristine, ifosfamide, and doxorubicin in the treatment of pediatric non-rhabdomyosarcoma soft tissue sarcomas. , 1998, 30, 210-216.		18
91	The role of adjuvant chemotherapy in the treatment of adult soft tissue sarcomas. <i>Critical Reviews in Oncology/Hematology</i> , 1998, 27, 221-227.	2.0	12

#	ARTICLE	IF	CITATIONS
92	Soft tissue sarcoma of the extremities. A multimodality diagnostic and therapeutic approach. <i>Cancer Treatment Reviews</i> , 1998, 24, 373-391.	3.4	42
93	Should patients with advanced carcinomas be treated with chemotherapy?. <i>European Journal of Cancer</i> , 1998, 34, 962-964.	1.3	5
94	Mode of Action of Ifosfamide – New Aspects. <i>Oncology Research and Treatment</i> , 1998, 21, 1-4.	0.8	4
95	Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas. <i>Annals of Oncology</i> , 1998, 9, 877-884.	0.6	43
96	Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: A study of the Spanish Group for Research on Sarcomas (GEIS). <i>Annals of Oncology</i> , 1998, 9, 871-876.	0.6	57
97	Dose-intensive chemotherapy with ifosfamide, epirubicin, and filgrastim for adult patients with metastatic or locally advanced soft tissue sarcoma: a phase II study.. <i>Journal of Clinical Oncology</i> , 1998, 16, 1438-1443.	0.8	97
98	Pilot Study of Daily Ifosfamide 1 g/m ² Until Grade III Granulocytopenia as Second-Line Chemotherapy for Anthracycline-Pre-treated Advanced Soft Tissue Sarcoma. <i>Tumori</i> , 1998, 84, 677-680.	0.6	1
99	Outcome and Toxicity of an Ifosfamide-Based Soft Tissue Sarcoma Treatment Protocol in Children. The Importance of Local Therapy. <i>Sarcoma</i> , 1998, 2, 171-177.	0.7	0
100	Evaluation of Dose-Intense Ifosfamide, with and Without Edatrexate, in Adults with Sarcoma. <i>Sarcoma</i> , 1999, 3, 121-127.	0.7	0
101	Lack of Activity of Docetaxel in Soft Tissue Sarcomas: Results of a Phase II Study of the Italian Group on Rare Tumors. <i>Sarcoma</i> , 1999, 3, 177-181.	0.7	8
102	The treatment of distant metastases in soft tissue sarcoma. <i>Seminars in Radiation Oncology</i> , 1999, 9, 389-400.	1.0	11
103	Soft Tissue Sarcoma. <i>Journal of Surgical Oncology</i> , 1999, 17, 1-1.	1.4	1
104	This letter was referred to the author, who responds as follows. <i>Annals of Oncology</i> , 1999, 10, 123-124.	0.6	0
105	Advanced soft tissue sarcoma: How many more trials with anthracyclines and ifosfamide?. <i>Annals of Oncology</i> , 1999, 10, 151-154.	0.6	21
106	The Role of Chemotherapy in the Treatment of Adult Soft Tissue Sarcomas. <i>Oncology</i> , 1999, 56, 13-23.	0.9	42
107	Safety and Efficacy of Adjuvant Single-Agent Ifosfamide in Uterine Sarcoma. <i>Gynecologic Oncology</i> , 2000, 78, 221-227.	0.6	33
108	Tumors of the Appendix and Colon. <i>World Journal of Surgery</i> , 2000, 24, 430-436.	0.8	32
109	Tumors of the Rectum and Anal Canal. <i>World Journal of Surgery</i> , 2000, 24, 437-443.	0.8	58

#	ARTICLE	IF	CITATIONS
110	Prognostic value of P-glycoprotein expression in bone and soft-tissue sarcoma. <i>International Journal of Clinical Oncology</i> , 2000, 5, 164-170.	1.0	7
111	Cyclophosphamide and Etoposide for Pediatric Solid Tumors. <i>Journal of Clinical Oncology</i> , 2000, 18, 3741-3743.	0.8	2
112	Randomized Phase III Study Comparing Conventional-Dose Doxorubicin Plus Ifosfamide Versus High-Dose Doxorubicin Plus Ifosfamide Plus Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor in Advanced Soft Tissue Sarcomas: A Trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. <i>Journal of Clinical Oncology</i> , 2000, 18, 2676-2684.	0.8	255
113	Docetaxel as Second-Line Chemotherapy for Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2000, 18, 3738-3739.	0.8	2
114	Fractionated Cyclophosphamide and Etoposide for Children With Advanced or Refractory Solid Tumors: A Phase II Window Study. <i>Journal of Clinical Oncology</i> , 2000, 18, 2576-2581.	0.8	12
115	Doxorubicin-Based Chemotherapy for the Palliative Treatment of Adult Patients with Locally Advanced or Metastatic Soft-Tissue Sarcoma: A Meta-Analysis and Clinical Practice Guideline. <i>Sarcoma</i> , 2000, 4, 103-112.	0.7	95
116	Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. <i>European Journal of Cancer</i> , 2000, 36, 61-67.	1.3	125
117	Cardiotoxicity of Chemotherapeutic Agents. <i>Drug Safety</i> , 2000, 22, 263-302.	1.4	606
118	Adjuvant Chemotherapy for Adult Soft Tissue Sarcomas of the Extremities and Girdles: Results of the Italian Randomized Cooperative Trial. <i>Journal of Clinical Oncology</i> , 2001, 19, 1238-1247.	0.8	631
119	Ifosfamide and Epirubicin Combination in Untreated Sarcomas: Two Treatment Schedules. <i>Oncology Research and Treatment</i> , 2001, 24, 465-468.	0.8	4
120	Concurrent ifosfamide-based chemotherapy and irradiation. <i>Cancer</i> , 2001, 92, 1550-1555.	2.0	38
121	Treatment of mandibular malignant fibrous histiocytoma during pregnancy. <i>Journal of Oral and Maxillofacial Surgery</i> , 2001, 59, 220-224.	0.5	12
122	The Use of Chemotherapy in Soft-Tissue Sarcomas. <i>Oncologist</i> , 2002, 7, 348-359.	1.9	102
123	Gene Therapy for Sarcoma. <i>Cells Tissues Organs</i> , 2002, 172, 133-144.	1.3	11
124	Treatment of Refractory Osteosarcoma With Fractionated Cyclophosphamide and Etoposide. <i>Journal of Pediatric Hematology/Oncology</i> , 2002, 24, 250-255.	0.3	35
125	The EORTC Soft Tissue and Bone Sarcoma Group. <i>European Journal of Cancer</i> , 2002, 38, 138-141.	1.3	39
126	Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. <i>European Journal of Cancer</i> , 2002, 38, 2397-2406.	1.3	158
127	Stem cell toxicity of oxazaphosphorine metabolites in comparison to their antileukemic activity. <i>Biochemical Pharmacology</i> , 2002, 63, 1337-1341.	2.0	4

#	ARTICLE	IF	CITATIONS
128	High-dose chemotherapy in adult soft tissue sarcoma. <i>Critical Reviews in Oncology/Hematology</i> , 2002, 41, 157-167.	2.0	38
129	Cisplatin-based chemotherapy regimen (DECAV) for uterine sarcomas. <i>International Journal of Gynecological Cancer</i> , 2002, 12, 749-754.	1.2	28
130	Cisplatin, doxorubicin and ifosfamide in carcinosarcoma of the female genital tract. A phase II study of the European Organization for Research and Treatment of Cancer Gynaecological Cancer Group (EORTC 55923). <i>European Journal of Cancer</i> , 2003, 39, 481-487.	1.3	37
131	Phase II Trial Of Pegylated-liposomal Doxorubicin (Doxilâ,,ç) In Sarcoma*. <i>Cancer Investigation</i> , 2003, 21, 167-176.	0.6	115
132	Treatment of Sarcomas: Thinking Out-of-the-Box. <i>Cancer Investigation</i> , 2003, 21, 321-322.	0.6	1
133	Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma. <i>The Cochrane Library</i> , 2003, , CD003293.	1.5	120
134	Soft Tissue Sarcoma. , 0, , 539-557.		0
135	Phase II and Pharmacokinetic Study of Ecteinascidin 743 in Patients With Progressive Sarcomas of Soft Tissues Refractory to Chemotherapy. <i>Journal of Clinical Oncology</i> , 2004, 22, 1480-1490.	0.8	280
136	Soft Tissue Sarcomas. <i>Ca-A Cancer Journal for Clinicians</i> , 2004, 54, 94-109.	157.7	468
137	Alternating sequential chemotherapy with high-dose ifosfamide and doxorubicin/cyclophosphamide for adult non-small round cell soft tissue sarcomas. <i>Journal of Orthopaedic Science</i> , 2005, 10, 258-263.	0.5	5
138	Ecteinascidin-743 (ET-743): Early Test or Effective Treatment in Soft Tissue Sarcomas?. <i>Journal of Clinical Oncology</i> , 2005, 23, 5420-5423.	0.8	15
139	Ecteinascidin-743 (ET-743) for Chemotherapy-Naive Patients With Advanced Soft Tissue Sarcomas: Multicenter Phase II and Pharmacokinetic Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 5484-5492.	0.8	173
140	Phase II Trial of Neoadjuvant Vincristine, Ifosfamide, and Doxorubicin With Granulocyte Colony-Stimulating Factor Support in Children and Adolescents With Advanced-Stage Nonrhabdomyosarcomatous Soft Tissue Sarcomas: A Pediatric Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 4031-4038.	0.8	99
141	Sarcomas and pharmacogenetics. <i>Pharmacogenomics</i> , 2005, 6, 585-601.	0.6	4
142	Metabolism and Transport of Oxazaphosphorines and the Clinical Implications. <i>Drug Metabolism Reviews</i> , 2005, 37, 611-703.	1.5	158
143	Activation of oxazaphosphorines by cytochrome P450: Application to gene-directed enzyme prodrug therapy for cancer. <i>Toxicology in Vitro</i> , 2006, 20, 176-186.	1.1	61
144	Ecteinascidin-743: Evidence of Activity in Advanced, Pretreated Soft Tissue and Bone Sarcoma Patients. <i>Sarcoma</i> , 2006, 2006, 1-11.	0.7	23
145	Chloroacetaldehyde: mode of antitumor action of the ifosfamide metabolite. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 57, 349-356.	1.1	27

#	ARTICLE	IF	CITATIONS
146	A phase II trial of O 6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 58, 634-639.	1.1	35
147	Clinical Pharmacology of Cyclophosphamide and Ifosfamide. <i>Current Drug Therapy</i> , 2006, 1, 55-84.	0.2	83
148	The Pharmacologic Basis of Ifosfamide Use in Adult Patients with Advanced Soft Tissue Sarcomas. <i>Oncologist</i> , 2007, 12, 1351-1360.	1.9	72
149	Osteomalacia as a Late Metabolic Complication of Ifosfamide Chemotherapy in Young Adults: Illustrative Cases and Review of the Literature. <i>Sarcoma</i> , 2007, 2007, 1-6.	0.7	11
151	Multidisciplinary Management of Metastatic Sarcoma. <i>Surgical Clinics of North America</i> , 2008, 88, 661-672.	0.5	17
152	Urological implications of cyclophosphamide and ifosfamide. <i>Scandinavian Journal of Urology and Nephrology</i> , 2008, 42, 309-317.	1.4	47
153	Soft Tissue Sarcoma. , 2008, , 2061-2085.		0
154	Results of the EICESS-92 Study: Two Randomized Trials of Ewing's Sarcoma Treatmentâ€”Cyclophosphamide Compared With Ifosfamide in Standard-Risk Patients and Assessment of Benefit of Etoposide Added to Standard Treatment in High-Risk Patients. <i>Journal of Clinical Oncology</i> , 2008, 26, 4385-4393.	0.8	236
155	Trabectedin: the evidence for its place in therapy in the treatment of soft tissue sarcoma. <i>Core Evidence</i> , 2009, 4, 191.	4.7	10
156	Long-Term Evaluation of Ifosfamide-Related Nephrotoxicity in Children. <i>Journal of Clinical Oncology</i> , 2009, 27, 5350-5355.	0.8	110
157	Ifosfamide nephrotoxicity in children: a mechanistic base for pharmacological prevention. <i>Expert Opinion on Drug Safety</i> , 2009, 8, 155-168.	1.0	44
158	Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients. , 2010, , CD006300.		5
159	Ambulatory administration of 5-day infusion ifosfamide+Âmesna: a pilot study in sarcoma patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 491-495.	1.1	11
160	Histology-driven chemotherapy of soft-tissue sarcoma. <i>Annals of Oncology</i> , 2010, 21, vii270-vii276.	0.6	43
161	Suppression of Plasma Glutathione Peroxidase Activity by Ifosfamide*. <i>Asia-Oceania Journal of Obstetrics and Gynaecology</i> , 1994, 20, 441-447.	0.0	3
162	Autologous hematopoietic stem cell transplantation following high-dose chemotherapy for non-rhabdomyosarcoma soft tissue sarcomas. , 2011, , CD008216.		7
163	Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients. , 2012, 12, CD006300.		3
165	Anticancer activity of stabilized palifosfamide in vivo. <i>Anti-Cancer Drugs</i> , 2012, 23, 173-184.	0.7	6

#	ARTICLE	IF	CITATIONS
166	Leiomyosarcoma of the rectum mimicking primary ovarian carcinoma: a case report. <i>Journal of Ovarian Research</i> , 2013, 6, 27.	1.3	10
167	Efficacy and safety of pharmacological interventions in second- or later-line treatment of patients with advanced soft tissue sarcoma: a systematic review. <i>BMC Cancer</i> , 2013, 13, 385.	1.1	38
168	Autologous hematopoietic stem cell transplantation following high dose chemotherapy for non-rhabdomyosarcoma soft tissue sarcomas. , 2013, , CD008216.		8
169	Cyclophosphamide Compared With Ifosfamide in Consolidation Treatment of Standard-Risk Ewing Sarcoma: Results of the Randomized Noninferiority Euro-EWING99-R1 Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 2440-2448.	0.8	136
170	Ifosfamide-Induced Fanconi's Syndrome. <i>Journal of Cancer Research and Practice</i> , 2014, 1, 46-49.	0.2	5
171	Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients. <i>The Cochrane Library</i> , 2015, 2015, CD006300.	1.5	11
172	Chemotherapy for Bone Sarcomas in Adults: The MD Anderson Experience. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e656-e660.	1.8	13
173	Preoperative Therapy for Extremity Soft Tissue Sarcomas. <i>Current Treatment Options in Oncology</i> , 2015, 16, 25.	1.3	16
174	A Systematic Literature Review of Adverse Events Associated with Systemic Treatments Used in Advanced Soft Tissue Sarcoma. <i>Sarcoma</i> , 2016, 2016, 1-13.	0.7	14
175	First-line treatment in advanced or metastatic disease: one size fits all or adapted to specific histiotypes?. <i>Current Opinion in Oncology</i> , 2016, 28, 323-330.	1.1	5
176	Unusual evolution of leiomyosarcoma of the rectum: a case report and review of the literature. <i>Journal of Medical Case Reports</i> , 2016, 10, 249.	0.4	10
177	Chemotherapy for Bone Sarcoma in Adults. <i>Journal of Oncology Practice</i> , 2016, 12, 208-216.	2.5	44
178	Investigating the heterogeneity of alkylating agents' efficacy and toxicity between sexes: A systematic review and meta-analysis of randomized trials comparing cyclophosphamide and ifosfamide (MAIAGE) Tj ETQq0 008gBT /Overlock 10		
179	Standardization of the infusion sequence of antineoplastic drugs used in the treatment of breast and colorectal cancers. <i>Einstein (Sao Paulo, Brazil)</i> , 2018, 16, eRW4074.	0.3	8
180	Determination of genotoxic and antigenotoxic effects of wild-grown Reishi mushroom (<i>Ganoderma lucidum</i>) using the hen's egg test for analysis of micronucleus induction. <i>Biotechnic and Histochemistry</i> , 2019, 94, 628-636.	0.7	4
181	Assessing the Role of Neoadjuvant Chemotherapy in Primary High-Risk Truncal/Extremity Soft Tissue Sarcomas: An Analysis of the Multi-institutional U.S. Sarcoma Collaborative. <i>Annals of Surgical Oncology</i> , 2019, 26, 3542-3549.	0.7	19
182	Sarcomas of Soft Tissue. , 2020, , 1655-1693.e11.		0
183	Oxazaphosphorines combined with immune checkpoint blockers: dose-dependent tuning between immune and cytotoxic effects. , 2020, 8, e000916.		1

#	ARTICLE	IF	CITATIONS
184	Comparison of first line chemotherapy regimens for advanced soft tissue sarcoma: a network meta-analysis. <i>Journal of Chemotherapy</i> , 2021, 33, 570-581.	0.7	2
185	Chemotherapy in advanced soft tissue sarcomas. <i>Cancer Treatment and Research</i> , 1989, 44, 75-92.	0.2	2
186	Hyperthermia and thermochemotherapy. <i>Cancer Treatment and Research</i> , 1993, 67, 143-160.	0.2	9
187	Changing concepts in the systemic treatment of locally advanced or metastatic soft tissue sarcomas. <i>Cancer Treatment and Research</i> , 1993, 67, 107-116.	0.2	2
188	Preoperative chemotherapy for soft tissue sarcomas of the extremities: The experience at the University of California, Los Angeles. <i>Cancer Treatment and Research</i> , 1993, 67, 135-141.	0.2	13
189	Soft Tissue Sarcomas of Children. <i>Cancer Treatment and Research</i> , 1991, 56, 149-165.	0.2	2
190	Chemotherapy for metastatic soft tissue sarcomas. <i>Cancer Treatment and Research</i> , 1997, 91, 157-172.	0.2	6
191	Systemic Therapy of Disseminated Soft Tissue Sarcomas. <i>Recent Results in Cancer Research</i> , 1995, 138, 147-159.	1.8	3
192	Chemotherapy in Advanced Soft Tissue Sarcoma – The EORTC Experience. , 1988, , 183-190.		3
193	Sarcomas of Soft Tissue. , 2014, , 1753-1791.e10.		3
194	Second Line Chemotherapy with Ifosfamide as Outpatient Treatment for Advanced Bladder Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1997, 20, 519-521.	0.6	46
195	A Feasibility, Toxicity, and Early Response Study of Etoposide, Ifosfamide, and Vincristine for the Treatment of Children with Rhabdomyosarcoma: A Report from the Intergroup Rhabdomyosarcoma Study (IRS) IV Pilot Study. <i>The American Journal of Pediatric Hematology/Oncology</i> , 1997, 19, 124-129.	1.3	46
196	Reduced argininosuccinate synthetase expression in refractory sarcomas: Impacts on therapeutic potential and drug resistance. <i>Oncotarget</i> , 2016, 7, 70832-70844.	0.8	10
197	Update on Systemic Therapy for Advanced Soft-Tissue Sarcoma. <i>Current Oncology</i> , 2020, 27, 25-33.	0.9	19
198	Pristimerin inhibits the proliferation of HT1080 fibrosarcoma cells by inducing apoptosis. <i>Oncology Letters</i> , 2020, 19, 2963-2970.	0.8	8
199	Sarcomas. , 2001, , 217-229.		0
200	Soft Tissue Sarcoma. , 2001, , 1753-1777.		0
202	General Statement as to Efficacy of Surgery/Chemotherapy/Radiation Therapy. , 2013, , 37-64.		2

#	ARTICLE	IF	CITATIONS
203	Soft Tissue Sarcomas. , 2013, , 311-318.		0
204	Sarcomas of Soft Tissueâ~†. , 2014, , .		0
205	A Pilot Study of Adriamycin, Dacarbazine and Ifosfamide in Advanced Adult Soft Tissue Sarcomas. , 1988, , 168-173.		0
206	Weichteiltumoren des Beckens. , 1991, , 291-299.		0
207	Systemic Treatment of Advanced or Metastatic Soft Tissue Sarcomas. Cancer Treatment and Research, 1991, 56, 75-91.	0.2	6
208	Zytostatische Chemotherapie der Weichteilsarkome im Erwachsenenalter â€” wann ist sie indiziert?. , 1992, , 93-101.		0
209	Retroperitoneale Weichteiltumoren. , 1994, , 361-383.		0
210	Retroperitoneale Weichteiltumoren. , 1997, , 543-564.		0
211	Soft-Tissue Sarcomas. , 1999, , 925-952.		0
212	General Statement as to Efficacy of Surgery, Chemotherapy, Radiation Therapy, and Immunotherapy. , 2016, , 41-74.		0
213	Chemotherapy and Other Systemic Approaches to Adult Sarcomas. , 2017, , 223-255.		0
215	6-day continuous infusion of high-dose ifosfamide with bone marrow growth factors in advanced refractory malignancies. Journal of Cancer Research and Clinical Oncology, 1997, 123, 227-231.	1.2	0